Commercial Insight Top 20 Cancer Therapeutics

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2006-07-03

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The Top 20 cancer therapeutics generated sales of $20.1 billion in 2005 across the seven markets, set to reach $27.4 billion by 2015. Cytotoxics currently constitute the majority, due to their long history in oncology and their key role in current treatment. By 2015, the majority of the Top 20 will consist of targeted therapies, whose place in cancer therapy will become increasingly established.


Scope

  • Overview of the current Top 20 cancer therapeutics market, including profiles of key products and events impacting each during 200515
  • Assessment of current and future opportunities and threats in the cancer market across the seven major pharmaceutical markets
  • Individual country, EU5 and seven-market sales forecasts from 2005 to 2015 for the leading cancer therapeutics
  • Detailed discussion of assumptions and events used in forecast analysis, plus three commercial impact and lifecycle management case studies


    • Report Highlights
    The Top 20 cancer therapeutics were worth nearly $20.1 billion in sales in 2005 across the seven major markets. Given that the entire oncology market including the supportive care classes across the seven major markets, was worth $34.6 billion in 2005, the Top 20 cancer therapeutics account for a significant proportion of sales, approximately 58%.

    In 2005, the cytotoxics represented the majority of the Top 20, due to their long history in oncology and applicability for use across a range of tumor types. By 2015, the targeted therapies will constitute the majority as their inclusion into standard treatment continues and as line extension and horizontal expansion strategies are implemented.

    Only the targeted therapies class is forecast to undergo positive sales growth between 2005 and 2015, as increased inclusion into standard regimens occurs. The cytotoxics and antihormonal therapies are set to experience negative sales growth to 2015, as patent expiries on key products occur and increasing levels of genericization erode sales.


    Reasons to Purchase

  • Understand market specific drivers and predict the future potential of key cancer therapeutics
  • Quantify the impact of key patent expiries and product launches, and identify opportunities and risks across the seven major markets
  • Adopt knowledge to drive strategic planning for mature products and optimize the market penetration of new entrants

    • Table of Contents

    Other users found this report page using the following search terms: targeted therapy cytotoxic Antihormonal suprefact price sanofi aventis bristolmyers

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.